BETA

NSE

Beta Drugs Limited

₹2,098.70+5.30 (+0.25%)Close, 25 Sept 2026

Key statistics

Open: ₹2,093.40
Day range: 2,065.70 – 2,117.90
52-week range: 990.10 – 2,807.90
From 52w high: -25.3%
Volume: 10.5K
Turnover: ₹2.2Cr
Delivery: 51.5%
Rel volume: 0.52×
RSI (14): 44.6
ATR (14): 108.89
SMA 50: 2,270.30
SMA 200: 1,685.98

Performance

1 day: +0.25%
1 week: +2.12%
1 month: -7.18%
3 months: -2.98%
6 months: +96.54%
1 year: +13.64%

Delivery percentage

Latest: 51.5%
20-day avg: 52.3%
1-year avg: 58.1%
Percentile: 8th
Range: 14.5–100.0%

Over the last 20 sessions BETA settled 52.3% of its traded quantity, which is above average for an NSE equity. Its one-year average is 58.1%, so recent sessions are running 5.8 points lower than usual. The latest session ranks higher than 8% of the 1,648 sessions on record for it.

What delivery percentage measures Scan the whole market on delivery

Fundamentals

Market cap: ₹2,334 Cr
P/E (TTM): 40.26
EPS (TTM): ₹52.12
Shares outstanding: 1.11Cr
Listed: 24 Nov 2025

Classification

Macro sector: Healthcare
Sector: Healthcare
Industry: Pharmaceuticals & Biotechnology
Basic industry: Pharmaceuticals

NSE publishes no history for this taxonomy, so it is today’s classification rather than the one that held in the past.

Growthlatest filed quarter Q1 FY27

Revenue YoY: —
Profit YoY: —
Revenue QoQ: +33.61%
Profit QoQ: +82.18%
Interest cost YoY: —

Compound growth

Not enough filed history for a compound growth rate yet.

Trailing-twelve-month figures against the same measure that many years earlier, on one reporting basis throughout. Blank where the filed history is too short or either end of the window was a loss — never a number built from less.

About

ISIN: INE351Y01019
Series: EQ
History from: 12 Oct 2017
Sessions: 2,070

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 25 Sept 2026.